1. Home
  2. ALLO vs BSVN Comparison

ALLO vs BSVN Comparison

Compare ALLO & BSVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • BSVN
  • Stock Information
  • Founded
  • ALLO 2017
  • BSVN 2004
  • Country
  • ALLO United States
  • BSVN United States
  • Employees
  • ALLO N/A
  • BSVN N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • BSVN Major Banks
  • Sector
  • ALLO Health Care
  • BSVN Finance
  • Exchange
  • ALLO Nasdaq
  • BSVN Nasdaq
  • Market Cap
  • ALLO 438.2M
  • BSVN 438.8M
  • IPO Year
  • ALLO 2018
  • BSVN 2018
  • Fundamental
  • Price
  • ALLO $1.82
  • BSVN $44.40
  • Analyst Decision
  • ALLO Strong Buy
  • BSVN Buy
  • Analyst Count
  • ALLO 10
  • BSVN 3
  • Target Price
  • ALLO $10.06
  • BSVN $46.00
  • AVG Volume (30 Days)
  • ALLO 3.1M
  • BSVN 35.9K
  • Earning Date
  • ALLO 03-13-2025
  • BSVN 01-16-2025
  • Dividend Yield
  • ALLO N/A
  • BSVN 2.03%
  • EPS Growth
  • ALLO N/A
  • BSVN 58.69
  • EPS
  • ALLO N/A
  • BSVN 4.84
  • Revenue
  • ALLO $43,000.00
  • BSVN $97,449,000.00
  • Revenue This Year
  • ALLO N/A
  • BSVN N/A
  • Revenue Next Year
  • ALLO N/A
  • BSVN N/A
  • P/E Ratio
  • ALLO N/A
  • BSVN $9.17
  • Revenue Growth
  • ALLO 26.47
  • BSVN 37.95
  • 52 Week Low
  • ALLO $1.78
  • BSVN $24.50
  • 52 Week High
  • ALLO $5.78
  • BSVN $50.26
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 36.69
  • BSVN 47.87
  • Support Level
  • ALLO $2.11
  • BSVN $41.50
  • Resistance Level
  • ALLO $2.10
  • BSVN $50.26
  • Average True Range (ATR)
  • ALLO 0.17
  • BSVN 1.78
  • MACD
  • ALLO -0.02
  • BSVN -0.00
  • Stochastic Oscillator
  • ALLO 5.69
  • BSVN 33.11

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

About BSVN Bank7 Corp. Common stock

Bank7 Corp is a full-service commercial bank focused on providing customers with exceptional service and meeting their banking needs through a wide variety of commercial and retail financial services. It offers deposit banking products, including commercial deposit services, commercial checking, money market, and other deposit accounts, and retail deposit services such as certificates of deposit, money market accounts, checking accounts, negotiable order of withdrawal accounts, savings accounts, and automated teller machine access. it offers commercial real estate lending, hospitality lending, energy lending, and commercial and industrial lending, and also provides consumer lending services to individuals.

Share on Social Networks: